Beginning a new drug discovery collaboration using Congruence’s globally recognized Revenir™ platform for the creation of small molecule modulators Expanded collaboration into Ono’s other priority areas of interest, including neurology and immunology, following the ongoing partnership in oncology Obtaining exclusive worldwide option rights for the discovery, development, and commercialization of small molecule modulators generated by […]
‘I’ve given up on working in hospitality. The 15,000 pay isn’t worth the stress’
...
Read moreDetails
